Kinetics of Circulating Tumor DNA in Lymphoma Treated by Immuno-chemotherapy
NCT ID: NCT06141772
Last Updated: 2026-01-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
24 participants
INTERVENTIONAL
2023-12-21
2025-04-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Circulating Tumor DNA Sequencing in Patients With Peripheral T-cell Lymphomas
NCT06089941
ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL
NCT06693830
Assessment of the Minimal Residual Disease in DLBCL From Cell-free Circulating DNA by NGS
NCT02339805
Circulating Tumor DNA in Primary Mediastinal Large B-cell Lymphoma (PMBL)
NCT04824950
R-CHOP14 or R-CHOP21 &Consolidation PET-Oriented Radiotherapy (RT) in DLBCL Patients
NCT03364439
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Modelizing the kinetics of ctDNA during this early timeframe could help to better predict chemo-sensitivity and better reflect genetic heterogeneity of the tumor, through release of a larger quantity of ctDNA compared to baseline.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Kinetics of circulating tumor DNA
Measure of the circulating tumor DNA
Blood assessment to measure the kinetics au circulating tumor DNA
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Measure of the circulating tumor DNA
Blood assessment to measure the kinetics au circulating tumor DNA
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diffuse Large B Cell Lymphoma
* TEP-TDM at diagnosis
* Inform Consent form signed
* Performance status 0 or 1
* Hospitalized on clinician decision for first cycle of R-CHOP or R-miniCHOP
Exclusion Criteria
* Patient under guardianship or curatorship
* Incapacity to understand the study or conform to the constraints of the study (language barrier, psychological barrier, geographic barrier…)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Henri Becquerel
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Fabrice Jardin, MD,PhD
Role: PRINCIPAL_INVESTIGATOR
Centre Henri Becquerel
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Henri Becquerel
Rouen, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CHB23.05
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.